A Phase 3 interventional study of Diclofenac Sodium gel, 1% and Voltaren® Gel in Osteoarthritis, sponsored by Glenmark Pharmaceuticals Ltd. India. Completed at 44 sites in United States. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2017-06-28.
Sponsored by Glenmark Pharmaceuticals Ltd. India · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,029 studies in Osteoarthritis with a site in United States — 116 open to participants now, 175 under way, 14 of them phase 3. Osteoarthritis · United States.
Among the 1,029 studies in Osteoarthritis with a site in United States, this one is the 23rd largest by enrollment of the 832 interventional ones that give a count, is one of 53 that started in 2015, is one of 128 in phase 3, and was the 574th registered.
2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.
Browse Osteoarthritis studies →116 of the 1,029 studies in Osteoarthritis with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
Margaret L Gourlay, MD, MPH · Sites in United States
Ages 50–64
Columbia University · Sites in United States
Ages 18+
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Sites in United States
Ages 18–89
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 35 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,029 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 64 · Phase 2 155 · Phase 3 143 · Phase 4 74
First in 1977; this study’s year is marked. 53 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,164 is above the median of 80 across 2,240 interventional studies indexed under Osteoarthritis.
Median enrollment 100 across the 832 interventional studies, 114 across the 188 observational. Of the 759 that completed or were terminated, 338 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
473 of 1,029 have an industry lead sponsor. The 10 most frequent:
Glenmark Pharmaceuticals Ltd. India is the lead sponsor of 16 studies on the registry; none are open to participants now.
Glenmark Pharmaceuticals Ltd. India has 1 study filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
60 of the studies in Osteoarthritis with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06269705Phase 3Pacira Pharmaceuticals, IncZILRETTA in Subjects With Shoulder Osteoarthritis | 2026-12 |
| NCT05992883Phase 3Mayo ClinicNSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis | 2026-12-31 |
| NCT07219771Phase 3Doron Therapeutics Inc.A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P) | 2027-06-30 |
| NCT06917404Phase 3Paradigm Biopharmaceuticals Ltd.A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain. | 2027-07 |
| NCT06003101Phase 3Massachusetts General HospitalEffect of PRP, PPP, & BMAC on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies | 2027-08-30 |
Add all 60 to your calendar (.ics) → With an account.
Among the 1,029 studies in Osteoarthritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence of Diclofenac Sodium Gel, 1% (Glenmark Pharmaceuticals Ltd) to Voltaren® Gel (Diclofenac Sodium topical gel) 1% (Novartis Consumer Health, Inc) in Patients with Osteoarthritis (OA) of the Knee
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
apply gel to the target knee
Drug: Diclofenac Sodium gel, 1%
apply gel to the target knee
Drug: Voltaren® Gel
apply gel to the target knee
Drug: Placebo
Absolute Change in the Total WOMAC (Western Ontario and McMaster Universities Arthritis Index) Pain Subscale Score for the Target Knee
The total WOMAC Pain Subscale score was determined by summing the individual scores from each of the five questions using a 5-point Likert scale (i.e., 'none'=0; 'mild'=1, 'moderate'=2; 'severe'=3; 'extreme'=4) comprising the WOMAC Pain Subscale Rating for the Target Knee.
Time frame: Baseline and week 4
| Milestone | Test | Reference | Placebo |
|---|---|---|---|
| Started | 385 | 392 | 387 |
| Completed | 381 | 374 | 373 |
| Not completed | 4 | 18 | 14 |
The total WOMAC Pain Subscale score was determined by summing the individual scores from each of the five questions using a 5-point Likert scale (i.e., 'none'=0; 'mild'=1, 'moderate'=2; 'severe'=3; 'extreme'=4) comprising the WOMAC Pain Subscale Rating for the Target Knee.
| units on a scale | Test | Reference |
|---|---|---|
| Absolute Change in the Total WOMAC (Western Ontario and McMaster Universities Arthritis Index) Pain Subscale Score for the Target Knee | 5.8 ± 3.96 | 5.9 ± 3.94 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Test | — | 0/383 (0%) | 28/383 (7.3%) |
| Reference | — | 2/382 (0.5%) | 26/382 (6.8%) |
| Placebo | — | 1/378 (0.3%) | 23/378 (6.1%) |
| Event | Test | Reference | Placebo |
|---|---|---|---|
| Right Ankle Surgery Due To Stair FallSurgical and medical procedures | 0/383 | 0/382 | 1/378 |
| Rib FractureInjury, poisoning and procedural complications | 0/383 | 1/382 | 0/378 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 0/383 | 1/382 | 0/378 |
| NauseaGastrointestinal disorders | 0/383 | 1/382 | 0/378 |
| L Ankle Surgery Secondary To Trimalleolar FractureSurgical and medical procedures | 0/383 | 1/382 | 0/378 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/383 | 0/382 | 0/378 |
| Event | Test | Reference | Placebo |
|---|---|---|---|
| HeadacheNervous system disorders | 28/383 | 26/382 | 23/378 |
A total of 1164 subjects were randomized in the study; however there were 21 subjects excluded from the safety population randomized who did not received dose. (Test=2, Reference=10, Placebo=9). Therefore the subject numbers are not consistent with any of the rows in the Participant Flow module.
| Age, Continuous(years) | Test | Reference | Placebo | Total |
|---|---|---|---|---|
| Mean | 56.2 ± 10.36 | 56.5 ± 10.68 | 56.7 ± 10.52 | 56.4 ± 10.51 |
| Sex: Female, Male(Participants) | Test | Reference | Placebo | Total |
|---|---|---|---|---|
| Female | 249 | 237 | 248 | 734 |
| Male | 134 | 145 | 130 | 409 |
The record gives a start of Aug 2015, a primary completion of Mar 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2017, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diclofenac Sodium Gel
Glenmark Pharmaceuticals Ltd. India